{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 41,
  "pageCount": 41,
  "prevPage": 40,
  "nextPage": null,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a three-column layout to categorize achievements into product, clinical, and financial pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/41",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Three consecutive quarters of all-time high Net Sales and Profit in Q2-Q4; Continued community market share growth; 53% Y/Y growth in hospital volume; Initiated PIFR-2 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61d7e623-e8f8-4930-9dd0-321eb31cbfd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "list",
      "text": "Sold TRELEGY ELLIPTA royalty interests for $1.1B upfront; Eliminated all debt, ~$650 million; Completed financial restructuring; Initiated $250 million capital return program",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83f1dd96-2ac3-45f6-9556-1fc2a459ca3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "list",
      "text": "In study 0170, prevented blood pressure drop and symptoms worsening in MSA; Aligned with FDA on new Phase 3 study; Three scientific platform presentations; Secured up to $40 million from Royalty Pharma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eabf85b0-f650-4375-8032-1e5f57861c80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Year-to-date through Q4’22; 2. Data from MSA patients... 3. Biaggioni I, et al. Abstract 34... MSA, multiple system atrophy; OHSA, orthostatic hypotension symptom assessment; PIFR, peak inspiratory flow rate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec2debe0-e1df-4319-b8c1-1bc0243c3b22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "2022: A Year of Transformation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5de3069b-5835-43a8-898d-e24ab37c4977",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "9c1627ff-7dab-4c99-b0d5-ecd5b481e659",
      "evidence": "List of key accomplishments in 2022",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}